 Connection
Frank Scott to Immunosuppressive Agents
This is a "connection" page, showing publications Frank Scott has written about Immunosuppressive Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.458 |
|
|
|
-
Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol. 2016 Feb; 152(2):164-72.
Score: 0.392
-
Scott FI, Osterman MT. Natalizumab for Crohn's Disease: Down but Not Out. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1926-8.
Score: 0.377
-
Scott FI, Vajravelu RK, Bewtra M, Mamtani R, Lee D, Goldberg DS, Lewis JD. The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):302-309.e11.
Score: 0.353
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.133
-
Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, Xie F, Yun H, Osterman MT, Curtis JR, Lewis JD. Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. Arthritis Rheumatol. 2016 10; 68(10):2403-11.
Score: 0.103
-
Agarwal A, Scott FI, Ahmad NA, Chandrasekhara V. Chronic immunosuppression does not potentiate the malignant progression of mucinous pancreatic cystic lesions. Pancreatology. 2016 Sep-Oct; 16(5):900-4.
Score: 0.101
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|